MarketCap
Facebook
X
Telegram
Country |
 USA |
IPO year |
1983 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBALSPB |
Shares |
538 M |
Market Cap[1] |
$ 218 B |
EBITDA (LTM) |
$ 11.9 B |
P/E (LTM) |
25.331981 |
P/S (LTM) |
7.924729 |
EPS (LTM) |
17.26 |
Amgen is a biopharmaceutical company founded in the USA in 1980. The company is engaged in the development and production of drugs for the treatment of serious diseases such as cancer, rheumatoid arthritis, and osteoporosis.
AMGN is a leading provider of biotechnology products and has over 20,000 employees worldwide. The company has operations in over 100 countries and produces its products in facilities around the world.
The main goal of Amgen is to improve the lives of patients by developing innovative drugs that help fight serious illnesses. The company invests billions of dollars annually in research and development to find new treatment options.
AMGN also advocates for sustainability and environmental protection. The company is committed to reducing its CO2 emissions and making its production processes as environmentally friendly as possible. Amgen is also involved in the community and supports various programs to improve healthcare and education.
Overall, Amgen is an innovative and responsible company dedicated to developing new treatment options for serious illnesses while also striving to protect the environment and support the community.
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
AnaptysBio
ANAB
|
$ 51.7 | 1.83 % | $ 1.5 B | Nasdaq Global Select Market,SPB | USA |
 |
Allakos
ALLK
|
- | - | $ 28.6 M | Nasdaq Global Select Market,SPB | USA |
 |
Bicycle Therapeutics plc
BCYC
|
$ 3.73 | 3.61 % | $ 258 M | Nasdaq Global Select Market |  Britain |
 |
Black Diamond Therapeutics
BDTX
|
$ 1.89 | 0.53 % | $ 107 M | Nasdaq Global Select Market,SPB | USA |
 |
Clovis Oncology
CLVS
|
- | -7.23 % | $ 13 M | Nasdaq Global Select Market | USA |
 |
Concert Pharmaceuticals
CNCE
|
- | - | $ 401 M | Nasdaq Global Market | USA |
 |
Rezolute
RZLT
|
$ 3.94 | 1.87 % | $ 299 M | Nasdaq Capital Market | USA |
 |
Evelo Biosciences
EVLO
|
- | -14.46 % | $ 27.9 M | Nasdaq Global Select Market | USA |
 |
BioLineRx Ltd.
BLRX
|
$ 2.52 | 1.17 % | $ 6.21 B | Nasdaq Capital Market |  Israel |
 |
BioMarin Pharmaceutical
BMRN
|
$ 61.35 | 0.06 % | $ 11.8 B | Nasdaq Global Select Market,SPB | USA |
 |
Benitec Biopharma
BNTC
|
$ 9.64 | 0.46 % | $ 449 M | Nasdaq Capital Market | USA |
 |
BioNTech SE
BNTX
|
$ 99.26 | 0.81 % | $ 24 B | Nasdaq Global Select Market |  Germany |
 |
Freeline Therapeutics Holdings plc
FRLN
|
- | - | $ 384 M | Nasdaq Global Select Market | Britain |
 |
Genocea Biosciences
GNCA
|
- | -15.0 % | $ 3.04 M | Nasdaq Global Select Market | USA |
 |
Burford Capital Limited
BUR
|
$ 3.63 | 3.93 % | $ 795 M | NYSE | Britain |
|
Amryt Pharma plc
AMYT
|
- | - | $ 621 M | Nasdaq Global Select Market | Britain |
 |
G1 Therapeutics
GTHX
|
- | - | $ 370 M | Nasdaq Global Select Market,SPB | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
$ 2.17 | 0.46 % | $ 3.57 M | NYSE American | Israel |
 |
Catalyst Biosciences
CBIO
|
$ 14.24 | 0.35 % | $ 1.27 B | Nasdaq Capital Market | USA |
 |
C4 Therapeutics
CCCC
|
$ 3.03 | 0.3 % | $ 251 M | Nasdaq Global Select Market | USA |
 |
Codexis
CDXS
|
$ 1.37 | 1.45 % | $ 119 M | Nasdaq Global Select Market | USA |
 |
Cerus Corporation
CERS
|
$ 2.61 | 0.38 % | $ 497 M | Nasdaq Global Market | USA |
 |
AbbVie
ABBV
|
$ 265.12 | 0.09 % | $ 469 B | NYSE,SPB | USA |
 |
Humanigen
HGEN
|
- | -81.12 % | $ 4.28 M | Nasdaq Global Select Market | USA |
 |
Coherus BioSciences
CHRS
|
$ 1.17 | 1.48 % | $ 137 M | Nasdaq Global Market | USA |
 |
AbCellera Biologics
ABCL
|
$ 12.65 | 2.76 % | $ 3.78 B | Nasdaq Global Select Market |  Canada |
 |
Abeona Therapeutics
ABEO
|
$ 5.43 | 2.65 % | $ 288 M | Nasdaq Capital Market | USA |
 |
Celldex Therapeutics
CLDX
|
$ 31.48 | 1.16 % | $ 2.09 B | Nasdaq Global Select Market | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
$ 4.12 | 1.98 % | $ 50.3 M | Nasdaq Capital Market | Israel |
 |
Фармсинтез
LIFE
|
- | - | - | MOEX |  Russia |
 |
Cellectar Biosciences
CLRB
|
$ 2.08 | 0.48 % | $ 5.43 M | Nasdaq Capital Market | USA |
 |
IGM Biosciences
IGMS
|
- | - | $ 76.9 M | Nasdaq Global Select Market,SPB | USA |
 |
IMV
IMV
|
- | - | $ 13.1 M | Nasdaq Global Select Market | Canada |
 |
Kinnate Biopharma
KNTE
|
- | - | $ 123 M | Nasdaq Global Select Market | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
- | - | $ 231 M | Nasdaq Global Market | USA |
 |
Karuna Therapeutics
KRTX
|
- | - | $ 12.2 B | Nasdaq Global Market,SPB | USA |
 |
Cocrystal Pharma
COCP
|
$ 1.15 | 1.67 % | $ 13 M | Nasdaq Capital Market | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
$ 84.95 | 0.13 % | $ 7.99 B | Nasdaq Global Select Market | USA |
 |
Collegium Pharmaceutical
COLL
|
$ 22.64 | 0.85 % | $ 717 M | Nasdaq Global Select Market | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
$ 118.51 | 4.93 % | $ 12.3 B | Nasdaq Capital Market,SPB | USA |
 |
Chimerix
CMRX
|
- | - | $ 756 M | Nasdaq Global Select Market | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
$ 7.45 | 0.19 % | $ 99.2 M | Nasdaq Global Market | USA |
 |
Curis
CRIS
|
$ 0.88 | 0.85 % | $ 11.6 M | Nasdaq Global Market | USA |
 |
CorMedix
CRMD
|
$ 7.77 | 1.04 % | $ 560 K | Nasdaq Global Market | USA |
 |
CRISPR Therapeutics AG
CRSP
|
$ 55.7 | 0.23 % | $ 5.01 B | Nasdaq Global Market,SPB |  Schweiz |
 |
Corvus Pharmaceuticals
CRVS
|
$ 11.8 | 8.21 % | $ 932 M | Nasdaq Global Market | USA |
|
Champions Oncology
CSBR
|
$ 4.95 | 0.38 % | $ 68.5 M | Nasdaq Capital Market | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
$ 4.88 | 0.62 % | $ 935 M | Nasdaq Global Select Market | Canada |
 |
Cue Biopharma
CUE
|
$ 32.85 | 3.6 % | $ 3.11 B | Nasdaq Capital Market,SPB | USA |
 |
CEL-SCI Corporation
CVM
|
$ 1.72 | 2.38 % | $ 13.8 M | NYSE American,SPB | USA |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.